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Summary MAC 16 is one of a series of mouse colon tumours originally induced by dimethylhydrazine. It is
a relatively slow growing subcutaneous adenocarcinoma which becomes necrotic as it grows and causes severe
body wasting in the host. This study has indicated that the tumour is resistant to a large number of standard
anti-cancer drugs but is highly responsive to the investigational agent flavone acetic acid (FAA). The levels of
FAA achieved in tumours are lower than those necessary for activity in vitro suggesting its mechanism of
action in vivo is not direct cytotoxicity. Responding tumours demonstrate massive tissue necrosis and those
which are not cured have viable tumour cells associated with tumour blood vessels. The anti-tumour effects
are accompanied by control of the host's cancer cachexia. The unique chemosensitivity of MAC 16 to FAA
suggests that this agent has a novel mechanism which may be dependent upon specific biological
characteristics of tumours.
Flavone acetic acid (FAA) is a novel anti-tumour agent
under early clinical investigation in Europe and the USA.
The rationale for the submission of this compound for
clinical trial was significant anti-tumour effects in solid
murine tumours (Corbett et al., 1986; Plowman et al., 1986;
Bibby et al., 1987a). Initial clinical investigations have
demonstrated that FAA is also devoid of bone marrow
toxicity (Kerr et al., 1986). MAC 16 is one of a panel of
mouse adenocarcinomas of the colon initially induced by
1,2-dimethylhydrazine (Haase et al., 1973). The tumour
system has been extensively used in experimental chemo-
therapy studies but the chemosensitivity of MAC 16 has not
been fully evaluated. Preliminary chemosensitivity studies
with MAC 16 (Ali et al., 1985) demonstrated that the
tumour was moderately responsive to 5-fluorouracil (5FU)
and cyclophosphamide but did not respond to methyl-
CCNU (MeCCNU) or mitozolomide. Implantation of
MAC 16 results in a significant loss of host body weight
without excessive tumour mass and without a concomitant
reduction of food intake by the host (Bibby et al., 1987b).
The present study examines the anti-tumour effects of FAA
and a series of standard anti-cancer agents on MAC 16 and
also investigates plasma and tumour levels of FAA.
Materials and methods
Animals
Pure strain NMRI mice (age 6-8 weeks) from our inbred
colony were used. They were fed on CRM Diet (Labsure,
UK) and water ad libitum.
Test compounds
FAA was a gift from Lipha (Lyon, France) via Prof. S.B.
Kaye, University of Glasgow, UK; MeCCNU and DTIC
were gifts from the National Cancer Institute, USA. Mito-
zolomide was a gift from Prof. M.F.G. Stevens, University
of Aston, UK; ThioTEPA from Lederle Laboratories,
Gosport, Hants, UK; 5-FU from Roche, Welwyn Garden
City, UK; cyclophosphamide from the Boehringer Corpor
ation, London, UK and chlorambucil from Dr D.E.V.
Wilman, Institute ofCancerResearch, Sutton, UK. FAA,cyclo-
phosphamide, thioTEPA and 5-FU were dissolved in 0.9%
sterile saline. Chlorambucil and MeCCNU were dissolved in
10% ethanol/arachis oil, and DTIC and mitozolomide were
suspended in arachis oil. Drugs were prepared at appropriate
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concentrations for a desired dose to be administered in
0.1ml per lOg body weight. Drugs were made up immedia-
tely before use and all injections were i.p.
Tumours
The development of several transplantable adenocarcinomas
of the large bowel in mice from primary tumours induced by
prolonged administration of 1,2,dimethylhydrazine has been
described elsewhere (Double et al., 1975). MAC 16 tumours
were excised from donor animals and placed in sterile 0.9%
saline containing streptomycin (2mgml-') and penicillin
(2000Uml-1) and cut into small fragments 1 x 2mm in
size. Fragments were implanted s.c. into the flank by means
of a trocar. Take rates are variable with good rates being
dependent on careful implantation of viable tumour frag-
ments. Positive takes can only be identified 2-3 weeks after
implantation.
Chemotherapy
Tumour bearing animals were allocated by restricted
randomisation into groups of 10. Chemotherapy did not
commence until the tumours could be reliably measured, i.e.
until they achieved minimum dimensions of 4 x 5mm. Thera-
peutic effects were assessed by twice weekly 2-dimensional
caliper measurements of the tumour. Tumour volume was
calculated from the formula a2 x b/2 where a is the smaller
diameter and b is the larger (Geran et al., 1972). Tumour
volumes were normalised with respect to starting volumes
and graphs of the relative tumour volumes against time were
plotted on semi-log graph paper.
Measurement of drug levels in plasma and MAC 16 tumours
Reagents Spectroscopic grade ethanol (BDH Chemicals,
Poole, Dorset, UK) p-dimethylaminobenzaldehyde (Sigma
Chemical Co., Poole, Dorset, UK) and triple distilled water
were used. Other agents were of analytical grade.
Sample collection Blood samples from three tumour bearing
mice at each time point were taken by cardiac puncture
under ether anaesthesia, collected into heparinised tubes,
centrifuged at 2000g and 40C for 10min and then separated
plasma was stored at -20° until analysis. The mice were
killed by cervical dislocation and rapidly dissected. Tumours
were immediately frozen in liquid nitrogen and stored at
-200C.
Sample extraction and chromatography FAA was extracted
from fluid samples using solid phase chromatography and
measured by an HPLC method described by Double et al.
(1986) and modified from Kerr et al. (1985). Tumour
Br. J. Cancer (1988), 58, 341-344342 M.C. BIBBY et al.
samples were mixed with 0.1M sodium acetate-acetic acid
buffer, pH4 (10% w/v) and homogenised using an Ultra-
turrax blender. Homogenates were centrifuged at 2500g and
4°C for 5min. The supernatants were separated and after the
addition of internal standard, p-dimethylaminobenzaldehyde
(100,ul at 100 ugml-') were extracted for analysis. Standard
curves were prepared by the addition of FAA to buffered
control mouse plasma (pH4) and plotting ratio of peak areas
of FAA to the internal standard against drug concentration.
Peaks were traced and integrated with an Isaac Model 42A
data module (Syborg Corporation, USA), an Apple IIE
Computer (Apple Computer Inc., USA) and Appligration II
Software (Dynamic Solutions Corporation, USA). The
curves were linear over the range 0.4 to 40 gml-1. The
assay was sensitive to drug concentrations down to
lOngml-l and recovery was >90%.
Pharmacokinetic analysis The area under the concentration
versus time curve (AUC) was calculated for plasma and
tumour samples using the trapezoid rule.
Results
MAC 16 is a moderately well differentiated adenocarcinoma
of the colon which has been serially passaged for a period of
8 years. During this time the tumour has remained histo-
logically unaltered. A small degree of central necrosis is
present in small tumours and this increases with tumour size.
The effects of a series of anti-cancer agents against MAC 16
at or close to maximum tolerated dose are presented in
Table I. No significant growth delay was demonstrated with
any of these agents at any dose level. Tolerance to chloram-
bucil, DTIC and MeCCNU and ThioTEPA was lower in
female mice bearing MAC 16 tumours than in normal
female NMRI mice.
The effects of FAA against MAC 16 are shown in Figure 1.
A dose of 300mgkg-1 is acutely toxic with 4 out of 10
deaths occurring in this group. Treatment with 200mgkg-1
on 0 and day 7 results in a highly significant growth delay
with 8 out of 10 mice in this group being cured and no drug
associated deaths. ThioTEPA at the LD1O produces a very
short cessation of tumour growth but tumour growth rapidly
returns to control level.
Growth of MAC 16 in untreated animals is accompanied
by a dramatic body weight loss (Figure 2). Treatment with
FAA causes a rapid recovery in body weight. The interim
anti-tumour effect caused by ThioTEPA at the LDIO is also
accompanied by a cessation of body weight loss, but the
rapid regrowth of the tumour is accompanied by a drop in
body weight until this group reaches the same mean body
weight as the untreated control group.
The histology of MAC 16 tumours which respond to FAA
but are not cured is shown in Figure 3. The normal
histology of the appropriate passage is shown in Figure 3a
and the effects of FAA on tumours of that passage are
shown in Figures 3b and 3c. The viable tumour cells are
associated with vessels within the tumour whereas the vast
Table I Effects of a series of standard anti-cancer agents against
MAC 16
MTD in
Drug normal Tumour
Dose associated female mice growth delay
Drug (mgkg') deaths (mgkg1) (days)
Chlorambucil 20 1/10 30 0
Cyclophosphamide 300 2/10 300 0
DTIC 200 2/10 300 0
5FU 120 2/10 120 0
MeCCNU 25 0/10 30 0
Mitozolomide 37.5 0/10 40 0
ThioTEPA 15 1/10 20 0
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Figure 1 Anti-tumour effects of flavone acetic acid and thio-
TEPA against established MAC 16 tumours.
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Figure 2 Effects of flavone acetic acid and thioTEPA on mean
body weight of MAC 16 bearing mice.
majority of the tumour cells are dead. Levels of FAA in the
plasma and MAC 16 tumours following i.p. administration
of 200mgkg-1 are given in Figure 4. AUCs are
2.17mghml- 1 and 0.50mghgl-1 for plasma and tumour
tissue respectively.
Discussion
Chemotherapy studies have demonstrated that MAC 16 is
unresponsive to a series of standard anti-cancer drugs.
Previous earlier chemosensitivity studies demonstrated that
early passages of MAC 16 responded modestly to 5FU and
cyclophosphamide (Ali et al. 1985) but mice bearing these
tumours were able to tolerate similar levels of these agents as
normal mice. The serial passage of the MAC 16 tumour line
has been biased by selection for the cachexia caused in
tumour bearing mice (Bibby et al. 1987b) and this appears to
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Figure 3 Histological effects of treatment of MAC tumours
with flavone acetic acid: a untreated, b regrowing tumour after a
long growth delay, c same tumour showing viable tumour cells
associated with a tumour blood vessel.
have influenced responses and drug tolerance. There are no
major histological differences between early and late tumour
passages and the degree of necrosis of the tumour relates to
tumour size. The histology, growth characteristics and resis-
tance of this tumour suggests it may be a clinically relevant
model for the evaluation of potential anti-cancer drugs.
The i.p. maximum tolerated dose (MTD) of FAA in
female NMRI mice bearing MAC 16 tumours was
200mgkg-1 whereas the MTD in non-tumour bearing mice
and those bearing other tumours of the MAC system was
300mgkg-1 (Bibby et al. 1987a). Previous experimental
chemotherapy studies have shown that FAA is most active
against other subcutaneous MAC tumours when adminis-
tered by a two dose schedule split by seven days (Bibby et al.
1987a). FAA is highly active against MAC 16 tumours by
this treatment schedule. Control of tumour growth is accom-
panied by a control of the tumour associated cachexia. The
small anti-tumour effect demonstrated by thioTEPA at a
toxic dose is also accompanied by a small effect on host
body weight. The unique chemosensitivity of MAC 16 to
FAA demonstrated in this study strengthens the suggestion
Hours
plasma (0) and MAC 16 tumours
injection of 200mgkg-1 (plasma,
of Corbett et al. (1986) that for the first time an agent has
been identified with a very broad, perhaps nearly universal
solid tumour activity.
The pharmacokinetic data in this study following a dose
of 200mgkg-1 FAA suggests that the anti-tumour effects
are not the result of a direct cytotoxic mechanism. Previous
in vitro studies with a variety of tumour cell lines indicate
that high drug concentrations and long exposure times are
necessary to achieve direct cytotoxicity (Bibby et al., 1987a;
Capolonga et al., 1987; Schroyens et al., 1987). Preliminary
studies in this laboratory have also demonstrated that
MAC 16 cells are resistant to FAA in vitro at experimentally
achievable drug levels in vivo.
Histological examination of MAC 16 tumours which are
not cured but are beginning to regrow after a long growth
delay demonstrates massive tumour necrosis with varying
degrees of haemorrhage. Viable cells are seen in close
proximity to tumour blood vessels.
Several possible mechanisms have now been described for
the action of FAA in subcutaneous tumours. Smith et al.
(1987) have described the induction of haemorrhagic necrosis
in mouse colon 26 and colon 38 tumours and suggest that
FAA may work in a similar fashion to tumour necrosis
factor (TNF). Ching and Baguley (1987) and Wiltrout (1987)
have also suggested that natural killer (NK) cells may be
involved in the mechanisms of action of FAA as it activates
NK cell activity in mice.
In preliminary studies in this laboratory with another
tumour line (Bibby et al,. 1987c) we have demonstrated that
tumour vasculature may be important in the action of FAA
as the anti-tumour effects become more marked as vascular
composition of viable tumour increases with time after
implantation. This may be simply because of better drug
delivery to established tumours but may also be an indica-
tion that tumour vasculature itself is involved as a compo-
nent of therapy. Studies on the role of tumour blood vessels
in the response to FAA are currently being undertaken.
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in mice may be related to altered platelet function following
FAA treatment.
In conclusion FAA is highly active in a mouse colon
tumour which is resistant to a number of standard anti-
cancer drugs. The tolerance of MAC 16 tumour bearers to
standard agents and FAA is impaired but responses are still
achieved with FAA. The anti-tumour effects are accompa-
nied by control of the tumour associated cachexia. The low
tumour concentrations and the unique chemosensitivity sug-
gest that FAA is working by a completely novel mechanism
for a chemotherapeutic agent. The plasma profiles associated
with activity against subcutaneous tumours in mice have
now been attained in man (Kerr et al., 1987) but no
responses have yet been seen suggesting that low dose
activity may be dependant upon specific biological character-
istics of experimental subcutaneous tumours.
Supported by Whyte Watson/Turner Cancer Research Trust,
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